Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
State Key Laboratory of Crop Stress Adaptation and Improvement, Henan University, Kaifeng, China.
Invest Ophthalmol Vis Sci. 2022 Feb 1;63(2):30. doi: 10.1167/iovs.63.2.30.
The purpose of this study was to explore the therapeutic role of heat shock protein 90 (Hsp90) in wound healing of injury cornea epithelium.
The right eye of C57BL/6N male mice were performed the debridement wounds in the center of the cornea using an algerbrush II blade. The injured area was determined by staining the cornea with fluorescein sodium and measured with image-J. Immunoblotting, ELISA and immunochemistry were used for determining protein expression. The quantitation PCR was performed to measure mRNA expression.
Hsp90α is upregulated at both the mRNA and protein levels, and is secreted extracellularly into the corneal stroma and tear film during the healing process after corneal injury in mice. This upregulation is associated with activation of HSF1. Administration of recombinant exogenous Hsp90α (eHsp90α) speeds up wound healing of injured corneal epithelium. The eHsp90α binds to low-density lipoprotein (LDL)-related protein-1 (LRP-1) on the corneal epithelial cells and increases phosphorylation of AKT at S473, which is associated with proliferation and migration corneal epithelial cells in vitro or vivo. Inhibition of AKT by its inhibitor LY294002 abolishes eHsp90α-induced migration and proliferation of corneal epithelial cells.
Hsp90α is upregulated and secreted after corneal injury and acts to promote the healing process. Recombinant Hsp90α may be a promising therapeutic drug candidate for corneal injury.
本研究旨在探讨热休克蛋白 90(Hsp90)在损伤角膜上皮愈合中的治疗作用。
使用 algerbrush II 刀片在 C57BL/6N 雄性小鼠右眼中央角膜进行清创伤口。用荧光素钠染色角膜确定损伤面积,并使用 image-J 进行测量。免疫印迹、ELISA 和免疫组织化学用于确定蛋白质表达。定量 PCR 用于测量 mRNA 表达。
Hsp90α 在 mRNA 和蛋白质水平均上调,并在小鼠角膜损伤后愈合过程中外泌到角膜基质和泪膜中。这种上调与 HSF1 的激活有关。重组外源性 Hsp90α(eHsp90α)的给药可加速受损角膜上皮的愈合。eHsp90α与角膜上皮细胞上的低密度脂蛋白(LDL)相关蛋白-1(LRP-1)结合,并增加 AKT 在 S473 的磷酸化,这与体外或体内角膜上皮细胞的增殖和迁移有关。AKT 的抑制剂 LY294002 抑制 eHsp90α诱导的角膜上皮细胞迁移和增殖。
角膜损伤后 Hsp90α 上调并分泌,并发挥促进愈合过程的作用。重组 Hsp90α可能是一种有前途的治疗角膜损伤的候选药物。